Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-28 @ 12:05 AM
Study NCT ID:
NCT00898794
Status:
UNKNOWN
Last Update Posted:
2013-08-07
First Post:
2009-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'D001760', 'term': 'Bleeding Time'}, {'id': 'D010974', 'term': 'Platelet Aggregation'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D010979', 'term': 'Platelet Function Tests'}, {'id': 'D006403', 'term': 'Hematologic Tests'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D001790', 'term': 'Blood Physiological Phenomena'}, {'id': 'D002943', 'term': 'Circulatory and Respiratory Physiological Phenomena'}, {'id': 'D018056', 'term': 'Hemorheology'}, {'id': 'D015539', 'term': 'Platelet Activation'}, {'id': 'D006487', 'term': 'Hemostasis'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2007-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-06', 'lastUpdateSubmitDate': '2013-08-06', 'studyFirstSubmitDate': '2009-05-09', 'studyFirstSubmitQcDate': '2009-05-09', 'lastUpdatePostDateStruct': {'date': '2013-08-07', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2009-05-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-05', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Influence of bevacizumab on platelet aggregation'}, {'measure': 'Influence of VEGF on platelet aggregation'}, {'measure': 'Influence of VEGF or bevacizumab on cyclooxygenesis'}, {'measure': 'Correlation between medication sequence and platelet aggregation'}]}, 'conditionsModule': {'keywords': ['unspecified adult solid tumor, protocol specific', 'unspecified childhood solid tumor, protocol specific'], 'conditions': ['Unspecified Adult Solid Tumor, Protocol Specific', 'Unspecified Childhood Solid Tumor, Protocol Specific']}, 'descriptionModule': {'briefSummary': 'RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.\n\nPURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.', 'detailedDescription': 'OBJECTIVES:\n\n* To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.\n* To determine the influence of VEGF on platelet aggregation.\n* To determine the influence of VEGF or bevacizumab on cyclooxygenesis.\n* To determine if the sequence of medication plays a role in platelet aggregation.\n\nOUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'healthyVolunteers': False, 'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\n* Receiving bevacizumab for cancer\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics'}, 'identificationModule': {'nctId': 'NCT00898794', 'briefTitle': 'Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'Influence of Bevacizumab and VEGF on Platelet Aggregation', 'orgStudyIdInfo': {'id': 'KSGR-GR-01-07'}, 'secondaryIdInfos': [{'id': 'CDR0000631252', 'type': 'REGISTRY', 'domain': 'PDQ (Physician Data Query)'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'bevacizumab', 'type': 'BIOLOGICAL'}, {'name': 'coagulation study', 'type': 'OTHER'}, {'name': 'laboratory biomarker analysis', 'type': 'OTHER'}, {'name': 'platelet aggregation test', 'type': 'OTHER'}]}, 'contactsLocationsModule': {'locations': [{'zip': 'CH-7000', 'city': 'Chur', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Roger von Moos, MD', 'role': 'CONTACT', 'email': 'roger.vonmoos@ksgr.ch', 'phone': '41-81-256-6646'}], 'facility': 'Kantonsspital Graubuenden', 'geoPoint': {'lat': 46.84986, 'lon': 9.53287}}], 'overallOfficials': [{'name': 'Roger von Moos, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Kantonsspital Graubuenden'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kantonsspital Graubuenden', 'class': 'OTHER'}}}}